All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
The all Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the all Hub cannot guarantee the accuracy of translated content. The all and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Amgen, Autolus, Jazz Pharmaceuticals, and Pfizer and supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View ALL content recommended for you
Anthony MoormanDuring the 25th Congress of the European Hematology Association (EHA), the ALL Hub spoke to Anthony Moorman, Newcastle University, Newcastle upon Tyne, UK. We asked, Is TKI therapy effective in patients with ABL-class fusion ALL?
Is TKI therapy effective in patients with ABL-class fusion ALL?
ABL-class fusions refer to a group of gene fusions that are observed in a small proportion of child patients with ALL, and fall under the group of BCR-ABL/Philadelphia-like ALL. These patients are associated with higher instances of relapse; efforts are underway to improve patient outcomes in this setting. This interview focuses on patients with ABL-class fusion ALL who were treated on the UKALL 2011 trial.